🔗 Share this article

A shadow market for unapproved slimming drugs is being driven by social media fitness personalities and sellers on messaging platforms, according to recent findings.

Investigational Treatment Acquiring Popularity Online

Retatrutide, which is still in clinical trials, is being advertised by online personalities for its alleged weight-reducing properties. Viewers are encouraged to message these accounts privately for source information, while also receiving promotional offers.

Thriving Trade on Messaging Platforms

Separately, a flourishing trade exists on messaging services, where communities with numerous of participants share comparison images, administration instructions and assertions of rapid British shipping. Sellers promote the drug there before redirecting customers to other platforms for purchases.

Understanding Retatrutide

Retatrutide is an experimental injectable developed by US drugmaker Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could help patients reduce up to 25% of their total weight. Referred to as the “triple G”, the substance is being promoted online as the successor to Ozempic.

Healthcare Professionals Express Worries

Nevertheless, physicians and pharmacists have warned that the distribution of what is still an unapproved drug in the UK is worrisome and could result in users administering products of uncertain source.

Several experts stated the popularity for retatrutide could be connected to the increasing cost of licensed weight loss products such as Mounjaro.

Regulatory Status and Implementation

Selling the unapproved drug on TikTok or Telegram is illegal in the UK, as it is an unlicensed drug that must not be promoted or supplied for human use under the British medical regulations.

Some influencers attempt to circumvent the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but advertising and supply can still breach pharmaceutical, advertising, and consumer laws, risking penalties, prosecution or prison.

Platform Response and Content Removal

According to the social media company, the platform has removed problematic content and banned related hashtags and query recommendations. The company said it was committed to keeping the service safe and investing in strengthening compliance measures.

Digital Marketplace Operations

Investigations also discovered communities with up to nine thousand participants marketing the experimental drug using Telegram's built-in discovery tool, which operates like a online catalog. Typing “retatrutide” instantly displays channels with thousands of users, filled with photos of slimming results, positive testimonials and step-by-step instructions for preparing or administering at residence.

After minutes of entering one community, a vendor shared contact information, where the majority of purchases occur. The seller sent an instruction manual and promised delivery within 48 hours. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one inquired about weight, medical conditions or past usage.

Product Information and Pricing

Inside these groups, posts show dark colored packages with Royal Mail labels, stating to contain new batches. One message stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, prepared at home with purified liquid, or ready-to-use pens typically priced at £160 for 20 milligrams. When asked how much time a pen should last, vendors give contradictory answers varying between a several days to “depends on your body”.

Platform Moderation and Security Measures

A spokesperson for the messaging service said it regularly moderated harmful material on its service including material that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Expert Warnings

“People are injecting substances they cannot confirm. Although the science behind this drug is valid, these online products may not contain what they claim,” said a pharmacy expert, the head of pharmacy at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the increase in demand to recent price rises for authorized slimming medications such as Mounjaro. “With costs increasing, individuals are using online platforms. But counterfeit treatments are highly dangerous. You cannot know what’s inside or whether the conditions they were produced in was sterile,” she said.

Her team has already encountered individuals injured by self-injection from unverified suppliers. “We understand the disappointment, but purchasing from messaging apps or communication platforms is gambling with your health,” stated the doctor. “These materials could be impure or incorrectly dosed.”

Producer Statement

A spokesperson from the pharmaceutical company said the substance was in third stage clinical trials and had not been evaluated or approved by any regulatory agency anywhere in the world. “Consequently at this time no one can sell [it] for human use,” they explained, adding that any item “falsely representing itself as a company investigational product not yet authorized … may subject patients to possibly serious medical dangers”.